Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases.

International journal of molecular sciences - 20 Mar 2026

Zhu Yinghua, Zhang Fangfang, Li Siping, Tian Zhihua, Jiang Zaixue, Lv Fen, Zeng Xiaomei, Zhou Zhongjun, Zhong Baimao, Peng Qi, Lu Xiaomei

Abstract excerpt

NLRP3-associated autoinflammatory diseases (NLRP3-AIDs) are rare autoinflammatory disorders caused by uncontrolled inflammasome activation. While IL-1β blockade is first-line therapy, many patients respond inadequately, highlighting a need for alternative strategies. Transcriptomic analysis was performed on immune cells from a patient with an NLRP3 L573W mutation. Functional validation of CD177 as a downstream...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GPI-Linked Proteins
Share to Inflammasomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-1beta

Share to Isoantigens

Share to Neutrophils

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to Receptors, Cell Surface

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 41898699
DOI: 10.3390/ijms27062841
PMCID: PMC13026191

Genes

NLRP3
CD177

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases.PMID 41898699Read ↗

A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses.Semantic proximity Read ↗

The leucine-rich repeat (LRR) domain of NLRP3 is required for NLRP3 inflammasome activation in macrophagesSemantic proximity Read ↗

A patent review of NLRP3 inhibitors to treat autoimmune diseasesSemantic proximity Read ↗

Differential role of the NLRP 3 inflammasome in infection and tumorigenesisSemantic proximity Read ↗

Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.Semantic proximity Read ↗

An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 Mutation Enhancing Binding to NEK7.Semantic proximity Read ↗

NLRP3-associated autoinflammatory diseases: Phenotypic and molecular characteristics of germline versus somatic mutations.Semantic proximity Read ↗

An NLRP3 Mutation Causes Arthropathy and Osteoporosis in Humanized Mice.Semantic proximity Read ↗

Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseasesSemantic proximity Read ↗

Functional diversity of <i>NLRP3</i> gain-of-function mutants associated with CAPS autoinflammationSemantic proximity Read ↗

Regnase-1 D141N mutation induces CD4+ T cell-mediated lung granuloma formation via upregulation of Pim2.Semantic proximity Read ↗

CD200R1 promotes interleukin-17 production by group 3 innate lymphoid cells by enhancing signal transducer and activator of transcription 3 activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.